申请人:De Nanteuil Guillaume
公开号:US20060223830A1
公开(公告)日:2006-10-05
A compound selected from those of formula (I):
wherein:
R
3
represents a hydrogen atom, and R
1
and R
2
together with the carbon atoms carrying them form a benzene, naphthalene or quinoline ring structure, each of the ring structures being optionally substituted,
or R
1
represents a hydrogen atom, and R
2
and R
3
together with the carbon atoms carrying them form a benzene, naphthalene or quinoline ring structure, each of the ring structures being optionally substituted, n represents 1 or 2,
—X— represents a group selected from —(CH
2
)
m
—O-Ak-, —(CH
2
)
m
—NR
4
-Ak-, —(CO)—NR
4
-Ak- and —(CH
2
)
m
—NR
4
-(CO)—,
m represents an integer between
1
and 6 inclusive, Ak represents an optionally substituted alkylene chain, and R
4
represents a hydrogen atom or an alkyl group, Ar represents an aryl or heteroaryl group, its enantiomers, diasteroisomers, and addition salts thereof with a pharmaceutically acceptable acid.
Medical products containing the same which are useful in the treatment of conditions requiring a serotonin reuptake inhibitor and/or NK
1
antagonist.
从公式(I)中选择的化合物:其中:R3代表氢原子,R1和R2与携带它们的碳原子一起形成苯、萘或喹啉环结构,每个环结构可选择地被取代,或R1代表氢原子,R2和R3与携带它们的碳原子一起形成苯、萘或喹啉环结构,每个环结构可选择地被取代,n代表1或2,-X-代表从-(CH2)m-O-Ak-、-(CH2)m-NR4-Ak-、-(CO)-NR4-Ak-和-(CH2)m-NR4-(CO)-中选择的基团,m代表1到6之间的整数,Ak代表可选择地取代的烷基链,R4代表氢原子或烷基基团,Ar代表芳基或杂环芳基基团,它的对映异构体、顺反异构体和与药用酸形成的加合物。含有这些化合物的医药产品在治疗需要血清素再摄取抑制剂和/或NK1拮抗剂的病症中有用。